Mild Cognitive Impairment – Epidemiology – Asia Pacific
Our forecasts are made on the basis of changing levels of exposure to known risk or protective factors rather than extrapolation of historical trends. Factors are included in our forecast model when the future effects of exposure can be reasonably quantified. The Factors table summarizes all of the factors that were considered for inclusion in our model.
Table of contents
- Mild Cognitive Impairment - Epidemiology - Asia Pacific
- Introduction
- Key Findings
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Total Prevalence of Mild Cognitive Impairment per 1,000 Among People Aged 65 or Older in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Relative Sizes of the Contributing Factors to the Trend in Total Prevalent Cases of Mild Cognitive Impairment over the Next Ten Years
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Total Prevalent Cases of Mild Cognitive Impairment by Subtype
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Related Market Assessment Reports
Report
Spinal Muscular Atrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weakness and is a leading genetic cause of death in infants. SMA is divided into four clinical subtypes…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
The treatment of early Alzheimer’s disease (AD) is being transformed by the launches of Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla), and additional disease-…
Report
Parkinson’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Parkinson’s Disease (US)
Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug classes, including…
